))
Tyler O’Malley on Validation of CB-CAPs Distinguishing SLE from Fibromyalgia
Manage episode 353516539 series 3428257
Content provided by Exagen Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Exagen Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
How can a multianalyte assay panel help distinguish SLE from fibromyalgia and chronic localized pain? And what impact does this have on rheumatologists working to help determine their patients’ conditions?
Join Exagen and Tyler O’Malley, Senior Director of Clinical Affairs for Exagen, as he breaks down the abstract, Multi-Center Validation of Cell-Bound Complement Activation Products a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia. Tyler dives into how the study came to be and its clinical importance to both providers and patients.
3 episodes
Share
